Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Yasutaka Chiba et al.|Annals of Oncology|2017Cited by 294
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Kazuto Nishio, Takayuki Takahama et al.|The Oncologist|2020Cited by 95
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1Yoshikane Nonagase, Junji Tsurutani|Oncotarget|2016Cited by 25
Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancerYoshikane Nonagase, Kazuhiko Nakagawa|Thoracic Cancer|2019Cited by 13